Attached files
| file | filename |
|---|---|
| EX-31.2 - CERTIFICATION - Cellular Biomedicine Group, Inc. | cmbg_ex312.htm |
| EX-31.1 - CERTIFICATION - Cellular Biomedicine Group, Inc. | cmbg_ex311.htm |
| EX-32.1 - CERTIFICATION - Cellular Biomedicine Group, Inc. | cmbg_ex321.htm |
| EX-10.11 - AMENDED AND RESTATED 2011 INCENTIVE STOCK OPTION PLAN - Cellular Biomedicine Group, Inc. | cmbg_ex1011.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Cellular Biomedicine Group, Inc. | Financial_Report.xls |
| 10-Q - QUARTERLY REPORT - Cellular Biomedicine Group, Inc. | cmbg_10q.htm |
Exhibit 99.1
Supplemental Pro-Forma Income Statement
|
Three Months Ended March 31, 2013
|
Three Months Ended March 31, 2012
|
|||||||||||||||||||||||
|
CBMG
|
EastBridge
|
Pro-forma
|
CBMG
|
EastBridge
|
Pro-forma
|
|||||||||||||||||||
|
As stated
|
Q1 2013
|
Consolidated
|
As stated
|
Q1 2012 |
Consolidated
|
|||||||||||||||||||
|
Revenues
|
$ | - | $ | - | $ | - | $ | 78,589 | $ | - | $ | 78,589 | ||||||||||||
|
Cost of goods sold
|
- | - | - | 27,690 | - | 27,690 | ||||||||||||||||||
|
Gross profit
|
- | - | - | 50,899 | - | 50,899 | ||||||||||||||||||
|
Operating expenses:
|
||||||||||||||||||||||||
|
General and administrative
|
5,071,917 | 212,770 | 5,284,687 | 696,511 | 212,831 | 909,342 | ||||||||||||||||||
|
Selling and marketing
|
28,701 | 18,392 | 47,093 | 29,721 | 13,464 | 43,185 | ||||||||||||||||||
|
Research and development
|
480,505 | - | 480,505 | 255,954 | - | 255,954 | ||||||||||||||||||
|
Total operating expenses
|
5,581,123 | 231,162 | 5,812,285 | 982,186 | 226,295 | 1,208,481 | ||||||||||||||||||
|
Operating loss
|
(5,581,123 | ) | (231,162 | ) | (5,812,285 | ) | (931,287 | ) | (226,295 | ) | (1,157,582 | ) | ||||||||||||
|
Other income (expense)
|
||||||||||||||||||||||||
|
Interest expense
|
(257,438 | ) | - | (257,438 | ) | - | 1,675 | 1,675 | ||||||||||||||||
|
Interest income
|
971 | 455 | 1,426 | 1,013 | - | 1,013 | ||||||||||||||||||
|
Gain on extinguishment of debt
|
- | - | - | - | 6,128 | 6,128 | ||||||||||||||||||
|
Other expense
|
(6,071 | ) | - | (6,071 | ) | - | (25,883 | ) | (25,883 | ) | ||||||||||||||
|
Total other income (expense)
|
(262,538 | ) | 455 | (262,083 | ) | 1,013 | (18,080 | ) | (17,067 | ) | ||||||||||||||
|
Loss before taxes
|
(5,843,661 | ) | (230,707 | ) | (6,074,368 | ) | (930,274 | ) | (244,375 | ) | (1,174,649 | ) | ||||||||||||
|
Income tax provision
|
- | - | - | - | - | - | ||||||||||||||||||
|
Net loss
|
$ | (5,843,661 | ) | $ | (230,707 | ) | $ | (6,074,368 | ) | $ | (930,274 | ) | $ | (244,375 | ) | $ | (1,174,649 | ) | ||||||
|
Other comprehensive income (loss):
|
||||||||||||||||||||||||
|
Cumulative translation adjustment
|
(1,960 | ) | - | (1,960 | ) | $ | 5,819 | - | 5,819 | |||||||||||||||
|
Unrecognized loss on investments
|
(620,880 | ) | (4,047,912 | ) | (4,668,791 | ) | - | (22,847 | ) | (22,847 | ) | |||||||||||||
|
Comprehensive net loss
|
$ | (6,466,501 | ) | $ | (4,278,619 | ) | $ | (10,745,119 | ) | $ | (924,455 | ) | $ | (267,222 | ) | $ | (1,191,677 | ) | ||||||
|
Earnings per share:
|
||||||||||||||||||||||||
|
Basic and diluted
|
$ | (1.25 | ) | $ | (0.54 | ) | $ | (1.30 | ) | $ | (0.32 | ) | $ | (0.16 | ) | $ | (0.27 | ) | ||||||
|
Weighted average common shares outstanding:
|
||||||||||||||||||||||||
|
Basic and diluted
|
4,668,283 | 429,009 | 4,668,283 | 2,877,825 | 1,548,917 | 4,426,742 | ||||||||||||||||||